Evaluation of Genomic Applications in Practice and Prevention (EGAPP) is a pilot project initiated by the CDC National Office of Public Health Genomics in the fall of 2004.  The project’s goal is to establish and evaluate a systematic, evidence-based process for assessing genetic tests and other applications of genomic technology in transition from research to clinical and public health practice. 

EGAPP aims to integrate:

• existing recommendations on implementation of genetic tests from professional organizations and advisory committees.^1,2,3,4  
• knowledge and experience gained from existing processes for evaluation and appraisal (e.g., US Preventive Services Task Force, CDC’s Task Force on Community Preventive Services), previous CDC initiatives (e.g., the ACCE process for assembling and analyzing data on genetic tests; http://www.cdc.gov/genomics/gtesting/ACCE/fbr.htm)⁵ , and the international health technology assessment experience.

The primary focus of the EGAPP Project is an independent, non-federal Working Group established in April, 2005. The Working Group is composed of 13 multidisciplinary experts in areas such as evidence-based review, clinical practice, public health, laboratory practice, genomics, epidemiology, economics, ethics, policy, and health technology assessment.

More information on EGAPP as well as links to EGAPP-sponsored evidence-based reviews and recommendations can be found on the independent EGAPP Working Group website: http://www.egappreviews.org. 

Contact Us
The EGAPP Working Group is interested in hearing from anyone wishing to provide public comments on any issue related to the evaluation of genetic tests or the activities of EGAPP Project.  Address comments to Sheri Jordan, Project Support Coordinator, at EGAPP@cdc.gov or 770-488-8374.